...
首页> 外文期刊>Journal of Ayub Medical College >EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT
【24h】

EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT

机译:糖尿性糖尿病酮症酸中毒和重症急性肾损伤,继而在1型糖尿病患者中不合用钠葡萄糖COTRANSPORTER-2抑制剂

获取原文
           

摘要

Sodium glucose Cotransporter-2 (SGLT2) inhibitors are a new class of drug approved for the treatment of type-2 diabetes; however they are also increasingly used off label in type-1 diabetic patients. SGLT2 Inhibitors work by increasing glucose excretion in urine. Euglycemic diabetic ketoacidosis (DKA) is potentially life threatening side effect as patients have normal glucose and minimal symptoms thus delaying diagnosis and treatment. Our case report highlights the risk of using SGLT2 inhibitors in type-1 diabetes and also supports the need for long term studies to define clear efficacy and complications of SGLT 2 inhibitors in both type-1 and type 2 diabetes mellitis.
机译:钠葡萄糖共转运蛋白2(SGLT2)抑制剂是一类被批准用于治疗2型糖尿病的新型药物。但是,它们也越来越多地用于1型糖尿病患者。 SGLT2抑制剂通过增加尿液中的葡萄糖排泄来发挥作用。血糖正常的糖尿病酮症酸中毒(DKA)具有潜在的威胁生命的副作用,因为患者的血糖正常且症状极少,从而延迟了诊断和治疗。我们的病例报告强调了在1型糖尿病中使用SGLT2抑制剂的风险,并支持需要进行长期研究以明确SGLT 2抑制剂在1型和2型糖尿病患者中的明确疗效和并发症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号